| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00378-1941-21 | 00378-1941 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 70710-1032-07 | 70710-1032 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 81481-0803-01 | 81481-0803 | Nogapendekin alfa inbakicept-pmln | ANKTIVA | 400.0 ug/.4mL | Immunotherapy | Cytokine | IL-15 (⍺,β,ɣ) | Intravesical | May 6, 2024 | In Use | |
| 76282-0700-47 | 76282-0700 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 10, 2024 | In Use | |
| 73535-0208-01 | 73535-0208 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | Nov 30, 2025 | No Longer Used |
| 59651-0347-21 | 59651-0347 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 70121-1754-07 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
| 76282-0699-47 | 76282-0699 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 60505-4535-01 | 60505-4535 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | Mar 8, 2023 | In Use |
| 70710-1033-08 | 70710-1033 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
| 72903-0853-01 | 72903-0853 | Mirvetuximab soravtansine | ELAHERE | 5.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | Intravenous | Nov 14, 2022 | In Use | |
| 63304-0045-22 | 63304-0045 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 12, 2023 | In Use | |
| 51991-0344-21 | 51991-0344 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 66302-0014-01 | 66302-0014 | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | Intravenous | Mar 10, 2015 | In Use | |
| 00006-5033-02 | 00006-5033 | Trastuzumab | Ontruzant | 150.0 mg/1 | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Apr 15, 2020 | Sep 30, 2023 | No Longer Used |
| 69448-0016-11 | 69448-0016 | Trastuzumab-strf | HERCESSI | 420.0 mg/20mL, 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
| 00074-1044-01 | 00074-1044 | Telisotuzumab Vedotin | EMRELIS | 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
| 51991-0343-01 | 51991-0343 | Pomalidomide | Pomalidomide | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 00078-0669-84 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | Feb 1, 2016 | In Use |
| 68727-0950-02 | 68727-0950 | Zanidatamab-hrii | ZIIHERA | 50.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2 | Intravenous | Nov 20, 2024 | In Use | |
| 51991-0342-01 | 51991-0342 | Pomalidomide | Pomalidomide | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2026 | In Use | |
| 00002-7678-01 | 00002-7678 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 21, 2014 | In Use | |
| 59572-0210-15 | 59572-0210 | Thalidomide | Thalomid | 100.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 20, 2003 | In Use | |
| 00024-0656-01 | 00024-0656 | Isatuximab | Sarclisa | 500.0 mg/25mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
| 70771-1679-01 | 70771-1679 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use |
Found 12250 results — Export these results
Home